A. Martínez Ortega

A. Martínez Ortega

Auto-generated profile, based on publicly available information

A. Martínez Ortega

Unidad de Aplicaciones Biomédicas y Farmacocinética, CIEMAT Avda, Complutense 40, Madrid, 28040, Spain

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2016 in Applied Radiation and Isotopes
Verified
Journal Article
Closed access
EGE. García-Toraño
E. García-Toraño
VPV. Peyrés
V. Peyrés
MRM. Roteta
M. Roteta
ASA.I. Sánchez-Cabezudo
A.I. Sánchez-Cabezudo
EREduardo Romero
Eduardo Romero
AOA. Martínez Ortega
A. Martínez Ortega

26 August 2018 in Contrast Media & Molecular Imaging
Verified
Journal Article
Open access
PDF file
Miguel Angel MorcilloMiguel Angel Morcillo
Miguel Angel Morcillo
AGAngel Garcia Garcia
Angel Garcia Garcia
MOMarta Oteo
Marta Oteo
EREduardo Romero
Eduardo Romero
NMNatalia Magro
Natalia Magro
JMJorge Luis Martinez-Torrecuadrada
Jorge Luis Martinez-Torrecuadrada
Pancreatic ductal adenocarcinoma (PDAC) continues to be one of the deadliest cancers for which optimal diagnostic tools are still greatly needed. Identification of PDAC-specific molecular markers would be extremely useful to improve disease diagnosis and follow-up. MT1-MMP has long been involved in pancreatic cancer, especially in tumour invasion and metastasis. In this study, we aim to ascertain the suitability of MT1-MMP as a biomarker for positron emission tomography (PET) imaging. Two probes were assessed and compared for this purpose, an MT1-MMP-specific binding peptide (MT1-AF7p) and a specific antibody (LEM2/15), labelled, respectively, with 68Ga and with 89Zr. PET imaging with both probes was conducted in patient-derived xenograft (PDX), subcutaneous and orthotopic, PDAC mouse models, and in a cancer cell line (CAPAN-2)-derived xenograft (CDX) model. Both radiolabelled tracers were successful in identifying, by means of PET imaging techniques, tumour tissues expressing MT1-MMP although they did so at different uptake levels. The 89Zr-DFO-LEM2/15 probe showed greater specific activity compared to the 68Ga-labelled peptide. The mean value of tumour uptake for the 89Zr-DFO-LEM2/15 probe (5.67 ± 1.11%ID/g, n=28) was 25–30 times higher than that of the 68Ga-DOTA-AF7p ones. Tumour/blood ratios (1.13 ± 0.51 and 1.44 ± 0.43 at 5 and 7 days of 89Zr-DFO-LEM2/15 after injection) were higher than those estimated for 68Ga-DOTA-AF7p probes (of approximately tumour/blood ratio = 0.5 at 90 min after injection). Our findings strongly point out that (i) the in vivo detection of MT1-MMP by PET imaging is a promising strategy for PDAC diagnosis and (ii) labelled LEM2/15 antibody is a better candidate than MT1-AF7p for PDAC detection.

1 January 2016 in Applied Radiation and Isotopes
Verified
Journal Article
Closed access
EREduardo Romero
Eduardo Romero
AMAlfonso Martínez
Alfonso Martínez
MOMarta Oteo
Marta Oteo
AGAngel Garcia Garcia
Angel Garcia Garcia
Miguel Angel MorcilloMiguel Angel Morcillo
Miguel Angel Morcillo

1 September 2016 in Applied Radiation and Isotopes
Verified
Journal Article
Closed access
EGE. García-Toraño
E. García-Toraño
VPV. Peyrés
V. Peyrés
MRM. Roteta
M. Roteta
ASA.I. Sánchez-Cabezudo
A.I. Sánchez-Cabezudo
EREduardo Romero
Eduardo Romero
AOA. Martínez Ortega
A. Martínez Ortega

1 November 2019 in Applied Radiation and Isotopes
Verified
Journal Article
Closed access
EGE. García-Toraño
E. García-Toraño
EREduardo Romero
Eduardo Romero
AOA. Martínez Ortega
A. Martínez Ortega